A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib

CompletedOBSERVATIONAL
Enrollment

111

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

January 30, 2023

Study Completion Date

January 30, 2023

Conditions
Breast CancerAdjuvant TherapyHER2-positive Breast Cancer
Trial Locations (25)

3000

Multidisciplinary Breast Unit of the University Hospital Leuven and Sint-Andries Hospital, Leuven

10000

University Hospital Center Zagreb, Department of Oncology, Breast Unit, Zagreb

46009

Instituto Valenciano de Oncología IVO, Servicio de Oncología Médica C/ Beltran Baguena, Valencia

80131

Istituto Nazionale Tumori Fondazione G. Pascale, Dipartimento di Senologia Via Mariano Semmola, Napoli

Unknown

Clinique Saint-Luc Bouge, Bouge

Jessa Ziekenhuis - Campus Virga Jesse, Hasselt

CHU Brest - Hôpital Morvan, Brest

Centre Bourgogne, Lille

Hopital Prive La Louviere, Lille

Ospedale San Donato- ASL 8 Arezzo, Arezzo

Ospedale Santa Croce, Fano

IRCCS Ospedale Policlinico San Martino, Genova

Azienda Ospedaliero Universitaria di Parma, Parma

Hospital Clinic Barcelona, Barcelona

Hospital Quironsalud Barcelona, Barcelona

Hospital Teknon Barcelona, Barcelona

Complejo Hospitalario de Jaén, Jaén

Hospital Universitari Arnau de Vilanova, Lleida

Hospital General Universitario Gregorio Marañon, Madrid

Hospital Ruber Internacional, Madrid

Hospital Universitario Clinico San Carlos, Madrid

Hospital General de Catalunya, Sant Cugat del Vallès

Hospital Universitario Marqués de Valdecilla, Santander

Hospital General Universitario de Valencia, Valencia

Hospital LLuís Alcanyís de Xàtiva, Valencia

All Listed Sponsors
collaborator

Iqvia Pty Ltd

INDUSTRY

lead

Pierre Fabre Medicament

INDUSTRY